|
Key figures – 1st quarter 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR million |
Pharma-ceuticals |
Chemicals |
Corporate |
Total |
Change |
|
Total revenues |
1,543.8 |
1,020.0 |
– |
2,563.8 |
22.1 |
|
Gross margin |
1,303.7 |
620.4 |
– |
1,924.1 |
19.3 |
|
Research and development |
–310.5 |
–69.0 |
– |
–379.5 |
9.3 |
|
Operating result |
156.1 |
240.8 |
–25.3 |
371.6 |
26.1 |
|
Exceptional items |
1.0 |
157.0 |
– |
158.0 |
– |
|
Earnings before interest and tax (EBIT) |
157.1 |
397.8 |
–25.3 |
529.5 |
79.6 |
|
EBIT before depreciation |
409.6 |
496.7 |
–23.9 |
882.5 |
63.1 |
|
Return on sales in % |
10.1 |
23.6 |
– |
14.5 |
|
|
Free cash flow |
551.2 |
350.1 |
–255.9 |
645.3 |
– |
|
Underlying free cash flow |
286.1 |
155.4 |
–255.9 |
185.6 |
–10.2 |
|
Underlying free cash flow on revenues (FCR) in % |
18.5 |
15.2 |
– |
7.2 |
|
